These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24968790)

  • 1. Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial.
    Akizawa T; Tsuruta Y; Okada Y; Miyauchi Y; Suda A; Kasahara H; Sasaki N; Maeda Y; Suzuki T; Matsui N; Niwayama J; Suzuki T; Hara H; Asano Y; Komemushi S; Fukagawa M
    BMC Nephrol; 2014 Jun; 15():98. PubMed ID: 24968790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.
    Savica V; Calò LA; Monardo P; Davis PA; Granata A; Santoro D; Savica R; Musolino R; Comelli MC; Bellinghieri G
    J Am Soc Nephrol; 2009 Mar; 20(3):639-44. PubMed ID: 19020004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salivary glands: a new player in phosphorus metabolism.
    Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
    J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease.
    Block GA; Persky MS; Shamblin BM; Baltazar MF; Singh B; Sharma A; Pergola P; Smits G; Comelli MC
    Nephron Clin Pract; 2013; 123(1-2):93-101. PubMed ID: 23797006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
    Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
    Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.
    Lee CT; Wu IW; Chiang SS; Peng YS; Shu KH; Wu MJ; Wu MS
    J Nephrol; 2015 Feb; 28(1):105-13. PubMed ID: 24840781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
    Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
    Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorus balance calculator: an individualized tool for treatment of hyperphosphatemia in hemodialysis patients.
    Wang M; Xiao J; Du Q; Zhang W; Zhang J; Yan Z; Luo J; Yu C; Ye Z; Chen J
    Nephrol Dial Transplant; 2024 Jun; 39(7):1159-1170. PubMed ID: 38037501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
    Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
    Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.
    Cheng SC; Young DO; Huang Y; Delmez JA; Coyne DW
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1131-8. PubMed ID: 18385391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients.
    Aramwit P; Srisawadwong R; Supasyndh O
    J Nephrol; 2012; 25(3):354-62. PubMed ID: 21748722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder.
    Calò LA; Savica V; Piccoli A; Fusaro M; D'Angelo A; Davis PA
    Ren Fail; 2011; 33(1):11-4. PubMed ID: 21219199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
    Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
    Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
    Sprague SM; Abboud H; Qiu P; Dauphin M; Zhang P; Finn W
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):178-85. PubMed ID: 19056618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.